Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Cyclophosphamide/Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02985333Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2014
- Primary completion
- Dec 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection in multiple myeloma (MM), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 30 months. Planned start Jan 2014; status: withdrawn.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02985333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985333.